Ipca Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023
May 29, 2023 at 04:09 am EDT
Share
Ipca Laboratories Limited reported earnings results for the fourth quarter and full year ended March 31, 2023. For the fourth quarter, the company reported sales was INR 15,116.3 million compared to INR 12,891 million a year ago. Revenue was INR 15,480.2 million compared to INR 13,036.4 million a year ago. Net income was INR 765.2 million compared to INR 1,302.3 million a year ago. Basic earnings per share from continuing operations was INR 3.02 compared to INR 5.13 a year ago. Diluted earnings per share from continuing operations was INR 3.02 compared to INR 5.13 a year ago.
For the full year, sales was INR 62,443.2 million compared to INR 58,297.9 million a year ago. Revenue was INR 63,699.4 million compared to INR 58,963.6 million a year ago. Net income was INR 4,713.2 million compared to INR 8,840.8 million a year ago. Basic earnings per share from continuing operations was INR 18.58 compared to INR 34.85 a year ago. Diluted earnings per share from continuing operations was INR 18.58 compared to INR 34.85 a year ago.
Ipca Laboratories Limited is an India-based pharmaceutical company. The Company is manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) covering various therapeutic segments. It offers APIs, such as Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts and Propranolol. The Company offers brands, such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, Venpower and Folitrax. The products of the Company are sold in over 100 countries across the globe. The Company has 18 manufacturing units in India manufacturing APIâs and formulations. Its subsidiaries include Ipca Pharmaceuticals, Inc., Ipca Laboratories (U.K.) Ltd and Tonira Exports Limited.
IPCA LABORATORIES LIMITED 
